Showing 708 results
-
Media Release /- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review…
-
Media Release /
-
Media Release /New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
-
Media Release /
-
Media Release /-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with…
-
Media Release /
-
Media Release /- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10…
-
Media Release /
-
Media Release /-- Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and older with uncontrolled moderate to severe persistent allergic asthma-- Asthma is one…
-
Media Release /
